Results 61 to 70 of about 9,825 (155)
ChemMedChem, Volume 21, Issue 11, 15 June 2026.Three series of pyrazole ribonucleoside analogues were designed and synthesized. They were evaluated, along with some of their pronucleotides, for their antiviral activity against RNA viruses. Pyrazole ribonucleoside analogues were prepared via a linear approach starting with the reaction of D‐ribosylhydrazine with 1,3‐dicarbonyl or acrylonitrile ...
Anaïs Guillou +6 more
wiley +1 more source
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
Biology, 2017 The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2.
Tatsuo Kanda +13 more
doaj +1 more source
Hepatitis E Virus Drug Development
Viruses, 2019 Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in ...
Volker Kinast +3 more
doaj +1 more source
Changing the face of hepatitis C management – the design and development of sofosbuvir
Drug Design, Development and Therapy, 2015 Bennett C Noell,* Siddesh V Besur,* Andrew S deLemos Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, Charlotte, NC, USA *These authors contributed equally to this work Abstract: The availability of
Noell BC, Besur SV, deLemos AS
doaj
Molecules, 2019 A simple, fast and highly sensitive RP-UPLC-MS/MS method was developed and validated for the simultaneous determination of sofosbuvir (SR) and its metabolite GS331007 in human plasma using ketotifen as an internal standard (IS).
Mohammad H. Semreen +3 more
doaj +1 more source
Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C
Journal of Rawalpindi Medical College, 2017 Background:To determine the effectiveness of sofosbuvir plus ribavirin in terms of frequency of negative qualitative PCR at 2nd week of treatment in chronic hepatitis C patients with genotype 3.
Aqsa Naseer
doaj
European Journal of Case Reports in Internal Medicine, 2015 Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment.
Rafael Mahieu +5 more
doaj +1 more source
Pakistan Armed Forces Medical Journal, 2020 Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them.
Sumetha Yaseen +5 more
doaj
ClinicoEconomics and Outcomes Research, 2015 David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat ...
Walker DR +4 more
doaj
ClinicoEconomics and Outcomes Research, 2017 Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY +8 more
doaj